ClinicalTrials.gg

Program

coramitug

Also written as “Coramitug” and “PRX004”.

Its studies are mostly in Amyloidosis, led by 2 companies.

Furthest: phase 1, since Feb 26, 20262 company-led studies, 1 open or runningNext primary completion: May 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk11 open or runningphase 1since Feb 26, 2026Feb 26, 2026May 30, 2027phase 1 · NCT07448623
Prothena Biosciences10 open or runningphase 1since Oct 23, 2017Oct 23, 2017none ahead
  • Named in Novo Nordisk’s own pipeline as Coramitug in ATTR-CM, phase 3, as of Nov 5, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 23, 2017First study: phase 1 study in AmyloidosisNew to Prothena BiosciencesProthena Biosciences · NCT03336580 · 21 enrolled · United States, Portugal, Spain and more
  2. Feb 26, 2026Novo Nordisk’s first study: phase 1 study in Transthyretin Amyloid CardiomyopathyNew to Novo NordiskNovo Nordisk · NCT07448623 · 14 planned · Netherlands

Ahead

  1. May 30, 2027Primary completion: phase 1 study in Transthyretin Amyloid CardiomyopathyNovo Nordisk · NCT07448623

TargetBeta

“Coramitug is a monoclonal antibody that potentially binds to the accumulations of the transthyretin protein and promotes its removal from the heart.”study summary, read by Claude · the study

Other programs on TTR

ProgramCompanyFurthest phaseStudies
tafamidisrulePfizerphase 429
acoramidisruleBridgeBiophase 415
coramitugNovo Nordiskphase 33

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07448623Transthyretin Amyloid Cardiomyopathy · Netherlands1RecruitingNovo NordiskMay 30, 202714
NCT03336580Amyloidosis · United States, Portugal, Spain and more1TerminatedProthena BiosciencesJul 23, 202021

How it is read

Names in the registry

  • “Coramitug”, 1 entry
  • “PRX004”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.